Study S002656

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, a Selective Glucagon-like Peptide (GLP) 1 Agonist, Following Subcutaneous Administration in Healthy Volunteers.

ClinicalTrials.gov record

Registration

Registration: NCT01972893
Acronym: ZYD1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 56
Start: 2011-02
Primary completion: 2012-03
Lead sponsor: Zydus Lifesciences Limited
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:ZYD1; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: OTHER:CTRI/2011/04/001684

Registered primary outcomes

To evaluate Safety and tolerability of ZYD1 [21 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.